Evidence map›Paper›PMID 33588835›Full record

ArticleJournal of nanobiotechnology2021

Tailored liposomal nanotraps for the treatment of Streptococcal infections.

Hervé Besançon, Viktoriia Babiychuk, Yu Larpin, René Köffel, Dominik Schittny, Lara Brockhus, Lucy J Hathaway, Parham Sendi, Annette Draeger, Eduard Babiychuk

Open access · goldAbstract read
In one paragraph

Article in Journal of nanobiotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Liposomal Nanotraps NeutralizeInfectious microbes & diseases · 2025
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Hervé BesançonInstitute of Anatomy, University of Bern, 3012, Bern, Switzerland.ORCID http://orcid.org/0000-0002-1426-1901
Viktoriia BabiychukInstitute of Anatomy, University of Bern, 3012, Bern, Switzerland.
Yu LarpinInstitute of Anatomy, University of Bern, 3012, Bern, Switzerland.
René KöffelInstitute of Anatomy, University of Bern, 3012, Bern, Switzerland.
Dominik SchittnyInstitute of Anatomy, University of Bern, 3012, Bern, Switzerland.
Lara BrockhusInstitute of Anatomy, University of Bern, 3012, Bern, Switzerland.
Lucy J HathawayInstitute for Infectious Diseases, University of Bern, 3001, Bern, Switzerland.
Parham SendiInstitute for Infectious Diseases, University of Bern, 3001, Bern, Switzerland.
Annette DraegerInstitute of Anatomy, University of Bern, 3012, Bern, Switzerland.
Eduard BabiychukInstitute of Anatomy, University of Bern, 3012, Bern, Switzerland. edik@ana.unibe.ch.
University of Bern · CH

Funding

CSRD VA 1Novartis Foundation 16B100
6 · The paper itself

Abstract

backgroundStreptococcal infections are associated with life-threatening pneumonia and sepsis. The rise in antibiotic resistance calls for novel approaches to treat bacterial diseases. Anti-virulence strategies promote a natural way of pathogen clearance by eliminating the advantage provided to bacteria by their virulence factors. In contrast to antibiotics, anti-virulence agents are less likely to exert selective evolutionary pressure, which is a prerequisite for the development of drug resistance. As part of their virulence mechanism, many bacterial pathogens secrete cytolytic exotoxins (hemolysins) that destroy the host cell by destabilizing their plasma membrane. Liposomal nanotraps, mimicking plasmalemmal structures of host cells that are specifically targeted by bacterial toxins are being developed in order to neutralize-by competitive sequestration-numerous exotoxins.

resultsIn this study, the liposomal nanotrap technology is further developed to simultaneously neutralize the whole palette of cytolysins produced by Streptococcus pneumoniae, Streptococcus pyogenes and Streptococcus dysgalactiae subspecies equisimilis-pathogens that can cause life-threatening streptococcal toxic shock syndrome. We show that the mixture of liposomes containing high amounts of cholesterol and liposomes composed exclusively of choline-containing phospholipids is fully protective against the combined action of exotoxins secreted by these pathogens.

conclusionsUnravelling the universal mechanisms that define targeting of host cells by streptococcal cytolysins paves the way for a broad-spectrum anti-toxin therapy that can be applied without a diagnostic delay for the treatment of bacterial infections including those caused by antibiotic-resistant pathogens.

Indexed as

Anti-Bacterial AgentsBacterial ToxinsDelayed DiagnosisHemolysin ProteinsHumansLiposomesStreptococcal InfectionsStreptococcusStreptococcus pyogenesAnti-Bacterial AgentsBacterial ToxinsHemolysin ProteinsLiposomesInfectionLiposomeNanotrapStreptococcusToxin

Identifiers

PMID33588835
PMCPMC7885208
OpenAlexW3131888809

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.